Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Tango Therapeutics (TNGX) Accumulated Depreciation & Amortization: 2020-2025

Historic Accumulated Depreciation & Amortization for Tango Therapeutics (TNGX) over the last 4 years, with Sep 2025 value amounting to $10.1 million.

  • Tango Therapeutics' Accumulated Depreciation & Amortization rose 29.92% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 34.78%. This contributed to the annual value of $8.4 million for FY2024, which is 39.64% up from last year.
  • As of Q3 2025, Tango Therapeutics' Accumulated Depreciation & Amortization stood at $10.1 million, which was up 4.68% from $9.6 million recorded in Q2 2025.
  • Over the past 5 years, Tango Therapeutics' Accumulated Depreciation & Amortization peaked at $10.1 million during Q3 2025, and registered a low of $2.3 million during Q3 2021.
  • For the 3-year period, Tango Therapeutics' Accumulated Depreciation & Amortization averaged around $7.2 million, with its median value being $7.1 million (2024).
  • Data for Tango Therapeutics' Accumulated Depreciation & Amortization shows a peak YoY surged of 68.16% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Tango Therapeutics' Accumulated Depreciation & Amortization stood at $2.5 million in 2021, then soared by 45.55% to $3.7 million in 2022, then soared by 62.70% to $6.0 million in 2023, then skyrocketed by 39.64% to $8.4 million in 2024, then rose by 29.92% to $10.1 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $10.1 million for Q3 2025, versus $9.6 million for Q2 2025 and $9.0 million for Q1 2025.